[12][14] These kinases provide activation signals, which play critical roles in proliferation, Ca2+ mobilization and cell differentiation.

[20][21][22] HSP90 inhibitor NVP-BEP800 has been described to affect stability of LYN kinase and growth of B-cell acute lymphoblastic leukemias through inhibition of the NF-kappaB signaling.

[23] LYN is reported to be a key signal mediator for estrogen-dependent suppression of human osteoclast differentiation, survival, and function.

[27][28] Tolimidone (MLR-1023) is a small molecule allosteric activator of lyn kinase with an EC50 of 63 nM[29][30] that is currently under Phase 2a investigation for Type II diabetes.

[36][37] Additional evidence suggest that lyn activation in alveolar phagocytes improves phagocytosis of bacteria and reduces pulmonary infection.

Lyn deficient mice display a phenotype that includes splenomegaly, a dramatic increase in numbers of myeloid progenitors and monocyte/macrophage tumors.

[13] Mice that expressed a hyperactive Lyn allele were tumor free and displayed no propensity toward hematological malignancy.